Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 48 entries
Sorted by: Best Match Show Resources per page
The dynamics of the human infant gut microbiome in development and in progression toward type 1 diabetes.

Cell host & microbe

Kostic AD, Gevers D, Siljander H, Vatanen T, Hyötyläinen T, Hämäläinen AM, Peet A, Tillmann V, Pöhö P, Mattila I, Lähdesmäki H, Franzosa EA, Vaarala O, de Goffau M, Harmsen H, Ilonen J, Virtanen SM, Clish CB, Orešič M, Huttenhower C, Knip M, Xavier RJ.
PMID: 25662751
Cell Host Microbe. 2015 Feb 11;17(2):260-73. doi: 10.1016/j.chom.2015.01.001. Epub 2015 Feb 05.

Colonization of the fetal and infant gut microbiome results in dynamic changes in diversity, which can impact disease susceptibility. To examine the relationship between human gut microbiome dynamics throughout infancy and type 1 diabetes (T1D), we examined a cohort...

Cite
Kostic AD, Gevers D, Siljander H, et al. The dynamics of the human infant gut microbiome in development and in progression toward type 1 diabetes. Cell Host Microbe. 2015;17(2):260-73doi: 10.1016/j.chom.2015.01.001.
Kostic, A. D., Gevers, D., Siljander, H., Vatanen, T., Hyötyläinen, T., Hämäläinen, A. M., Peet, A., Tillmann, V., Pöhö, P., Mattila, I., Lähdesmäki, H., Franzosa, E. A., Vaarala, O., de Goffau, M., Harmsen, H., Ilonen, J., Virtanen, S. M., Clish, C. B., Orešič, M., Huttenhower, C., Knip, M., & Xavier, R. J. (2015). The dynamics of the human infant gut microbiome in development and in progression toward type 1 diabetes. Cell host & microbe, 17(2), 260-73. https://doi.org/10.1016/j.chom.2015.01.001
Kostic, Aleksandar D, et al. "The dynamics of the human infant gut microbiome in development and in progression toward type 1 diabetes." Cell host & microbe vol. 17,2 (2015): 260-73. doi: https://doi.org/10.1016/j.chom.2015.01.001
Kostic AD, Gevers D, Siljander H, Vatanen T, Hyötyläinen T, Hämäläinen AM, Peet A, Tillmann V, Pöhö P, Mattila I, Lähdesmäki H, Franzosa EA, Vaarala O, de Goffau M, Harmsen H, Ilonen J, Virtanen SM, Clish CB, Orešič M, Huttenhower C, Knip M, Xavier RJ. The dynamics of the human infant gut microbiome in development and in progression toward type 1 diabetes. Cell Host Microbe. 2015 Feb 11;17(2):260-73. doi: 10.1016/j.chom.2015.01.001. Epub 2015 Feb 05. PMID: 25662751; PMCID: PMC4689191.
Copy Download .nbib Format: NLM
Lipid-Filled semipermeable membrane devices and mussels as samplers of organochlorine compounds in lake water.

Environmental science and pollution research international

Herve S, Prest HF, Heinonen P, Hyötyläinen T, Koistinen J, Paasivirta J.
PMID: 24234466
Environ Sci Pollut Res Int. 1995 Jul;2(1):24-30. doi: 10.1007/BF02987507.

Semipermeable membrane sampling devices (SPMDs) and caged lake mussels (Anodonta piscinalis) were simultaneously deployed at four lake watercourse sites in Central Finland four weeks in August 1992. This study was part of the regular annual monitoring of the organochlorine...

Cite
Herve S, Prest HF, Heinonen P, et al. Lipid-Filled semipermeable membrane devices and mussels as samplers of organochlorine compounds in lake water. Environ Sci Pollut Res Int. 1995;2(1):24-30doi: 10.1007/BF02987507.
Herve, S., Prest, H. F., Heinonen, P., Hyötyläinen, T., Koistinen, J., & Paasivirta, J. (1995). Lipid-Filled semipermeable membrane devices and mussels as samplers of organochlorine compounds in lake water. Environmental science and pollution research international, 2(1), 24-30. https://doi.org/10.1007/BF02987507
Herve, S, et al. "Lipid-Filled semipermeable membrane devices and mussels as samplers of organochlorine compounds in lake water." Environmental science and pollution research international vol. 2,1 (1995): 24-30. doi: https://doi.org/10.1007/BF02987507
Herve S, Prest HF, Heinonen P, Hyötyläinen T, Koistinen J, Paasivirta J. Lipid-Filled semipermeable membrane devices and mussels as samplers of organochlorine compounds in lake water. Environ Sci Pollut Res Int. 1995 Jul;2(1):24-30. doi: 10.1007/BF02987507. PMID: 24234466.
Copy Download .nbib Format: NLM
Prenatal exposure to poly-/per-fluoroalkyl substances is associated with alteration of lipid profiles in cord-blood.

Metabolomics : Official journal of the Metabolomic Society

Sinisalu L, Yeung LWY, Wang J, Pan Y, Dai J, Hyötyläinen T.
PMID: 34816353
Metabolomics. 2021 Nov 24;17(12):103. doi: 10.1007/s11306-021-01853-9.

INTRODUCTION: Poly-/per-fluoroalkyl substances (PFAS) are widespread environmental pollutants that may induce metabolic perturbations in humans, including particularly alterations in lipid profiles. Prenatal exposure to PFAS can cause lasting effects on offspring metabolic health, however, the underlying mechanisms are still...

Cite
Sinisalu L, Yeung LWY, Wang J, et al. Prenatal exposure to poly-/per-fluoroalkyl substances is associated with alteration of lipid profiles in cord-blood. Metabolomics. 2021;17(12):103doi: 10.1007/s11306-021-01853-9.
Sinisalu, L., Yeung, L. W. Y., Wang, J., Pan, Y., Dai, J., & Hyötyläinen, T. (2021). Prenatal exposure to poly-/per-fluoroalkyl substances is associated with alteration of lipid profiles in cord-blood. Metabolomics : Official journal of the Metabolomic Society, 17(12), 103. https://doi.org/10.1007/s11306-021-01853-9
Sinisalu, Lisanna, et al. "Prenatal exposure to poly-/per-fluoroalkyl substances is associated with alteration of lipid profiles in cord-blood." Metabolomics : Official journal of the Metabolomic Society vol. 17,12 (2021): 103. doi: https://doi.org/10.1007/s11306-021-01853-9
Sinisalu L, Yeung LWY, Wang J, Pan Y, Dai J, Hyötyläinen T. Prenatal exposure to poly-/per-fluoroalkyl substances is associated with alteration of lipid profiles in cord-blood. Metabolomics. 2021 Nov 24;17(12):103. doi: 10.1007/s11306-021-01853-9. PMID: 34816353; PMCID: PMC8610959.
Copy Download .nbib Format: NLM
Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride.

Cardiovascular diabetology

Jendle J, Hyötyläinen T, Orešič M, Nyström T.
PMID: 34920733
Cardiovasc Diabetol. 2021 Dec 17;20(1):237. doi: 10.1186/s12933-021-01431-2.

BACKGROUND: Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) leads to multiple metabolic changes, reduction in glucose levels and body weight are well established. In people with type 2 diabetes, GLP-1 RAs reduce the risk of cardiovascular (CV) disease...

Cite
Jendle J, Hyötyläinen T, Orešič M, et al. Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride. Cardiovasc Diabetol. 2021;20(1):237doi: 10.1186/s12933-021-01431-2.
Jendle, J., Hyötyläinen, T., Orešič, M., & Nyström, T. (2021). Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride. Cardiovascular diabetology, 20(1), 237. https://doi.org/10.1186/s12933-021-01431-2
Jendle, J, et al. "Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride." Cardiovascular diabetology vol. 20,1 (2021): 237. doi: https://doi.org/10.1186/s12933-021-01431-2
Jendle J, Hyötyläinen T, Orešič M, Nyström T. Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride. Cardiovasc Diabetol. 2021 Dec 17;20(1):237. doi: 10.1186/s12933-021-01431-2. PMID: 34920733; PMCID: PMC8684205.
Copy Download .nbib Format: NLM
Prenatal exposure to poly-/per-fluoroalkyl substances is associated with alteration of lipid profiles in cord-blood.

Metabolomics : Official journal of the Metabolomic Society

Sinisalu L, Yeung LWY, Wang J, Pan Y, Dai J, Hyötyläinen T.
PMID: 34816353
Metabolomics. 2021 Nov 24;17(12):103. doi: 10.1007/s11306-021-01853-9.

INTRODUCTION: Poly-/per-fluoroalkyl substances (PFAS) are widespread environmental pollutants that may induce metabolic perturbations in humans, including particularly alterations in lipid profiles. Prenatal exposure to PFAS can cause lasting effects on offspring metabolic health, however, the underlying mechanisms are still...

Cite
Sinisalu L, Yeung LWY, Wang J, et al. Prenatal exposure to poly-/per-fluoroalkyl substances is associated with alteration of lipid profiles in cord-blood. Metabolomics. 2021;17(12):103doi: 10.1007/s11306-021-01853-9.
Sinisalu, L., Yeung, L. W. Y., Wang, J., Pan, Y., Dai, J., & Hyötyläinen, T. (2021). Prenatal exposure to poly-/per-fluoroalkyl substances is associated with alteration of lipid profiles in cord-blood. Metabolomics : Official journal of the Metabolomic Society, 17(12), 103. https://doi.org/10.1007/s11306-021-01853-9
Sinisalu, Lisanna, et al. "Prenatal exposure to poly-/per-fluoroalkyl substances is associated with alteration of lipid profiles in cord-blood." Metabolomics : Official journal of the Metabolomic Society vol. 17,12 (2021): 103. doi: https://doi.org/10.1007/s11306-021-01853-9
Sinisalu L, Yeung LWY, Wang J, Pan Y, Dai J, Hyötyläinen T. Prenatal exposure to poly-/per-fluoroalkyl substances is associated with alteration of lipid profiles in cord-blood. Metabolomics. 2021 Nov 24;17(12):103. doi: 10.1007/s11306-021-01853-9. PMID: 34816353; PMCID: PMC8610959.
Copy Download .nbib Format: NLM
Links between central CB1-receptor availability and peripheral endocannabinoids in patients with first episode psychosis.

NPJ schizophrenia

Dickens AM, Borgan F, Laurikainen H, Lamichhane S, Marques T, Rönkkö T, Veronese M, Lindeman T, Hyötyläinen T, Howes O, Hietala J, Orešič M.
PMID: 32848142
NPJ Schizophr. 2020 Aug 26;6(1):21. doi: 10.1038/s41537-020-00110-7.

There is an established, link between psychosis and metabolic abnormalities, such as altered glucose metabolism and dyslipidemia, which often precede the initiation of antipsychotic treatment. It is known that obesity-associated metabolic disorders are promoted by activation of specific cannabinoid...

Cite
Dickens AM, Borgan F, Laurikainen H, et al. Links between central CB1-receptor availability and peripheral endocannabinoids in patients with first episode psychosis. NPJ Schizophr. 2020;6(1):21doi: 10.1038/s41537-020-00110-7.
Dickens, A. M., Borgan, F., Laurikainen, H., Lamichhane, S., Marques, T., Rönkkö, T., Veronese, M., Lindeman, T., Hyötyläinen, T., Howes, O., Hietala, J., & Orešič, M. (2020). Links between central CB1-receptor availability and peripheral endocannabinoids in patients with first episode psychosis. NPJ schizophrenia, 6(1), 21. https://doi.org/10.1038/s41537-020-00110-7
Dickens, Alex M, et al. "Links between central CB1-receptor availability and peripheral endocannabinoids in patients with first episode psychosis." NPJ schizophrenia vol. 6,1 (2020): 21. doi: https://doi.org/10.1038/s41537-020-00110-7
Dickens AM, Borgan F, Laurikainen H, Lamichhane S, Marques T, Rönkkö T, Veronese M, Lindeman T, Hyötyläinen T, Howes O, Hietala J, Orešič M. Links between central CB1-receptor availability and peripheral endocannabinoids in patients with first episode psychosis. NPJ Schizophr. 2020 Aug 26;6(1):21. doi: 10.1038/s41537-020-00110-7. PMID: 32848142; PMCID: PMC7450081.
Copy Download .nbib Format: NLM
Lipidomic and Metabolomic Signature of Progression of Chronic Kidney Disease in Patients with Severe Obesity.

Metabolites

Lanzon B, Martin-Taboada M, Castro-Alves V, Vila-Bedmar R, González de Pablos I, Duberg D, Gomez P, Rodriguez E, Orešič M, Hyötyläinen T, Morales E, Ruperez FJ, Medina-Gomez G.
PMID: 34940593
Metabolites. 2021 Dec 03;11(12). doi: 10.3390/metabo11120836.

Severe obesity is a major risk for chronic kidney disease (CKD). Early detection and careful monitoring of renal function are critical for the prevention of CKD during obesity, since biopsies are not performed in patients with CKD and diagnosis...

Cite
Lanzon B, Martin-Taboada M, Castro-Alves V, et al. Lipidomic and Metabolomic Signature of Progression of Chronic Kidney Disease in Patients with Severe Obesity. Metabolites. 2021;11(12)doi: 10.3390/metabo11120836.
Lanzon, B., Martin-Taboada, M., Castro-Alves, V., Vila-Bedmar, R., González de Pablos, I., Duberg, D., Gomez, P., Rodriguez, E., Orešič, M., Hyötyläinen, T., Morales, E., Ruperez, F. J., & Medina-Gomez, G. (2021). Lipidomic and Metabolomic Signature of Progression of Chronic Kidney Disease in Patients with Severe Obesity. Metabolites, 11(12), . https://doi.org/10.3390/metabo11120836
Lanzon, Borja, et al. "Lipidomic and Metabolomic Signature of Progression of Chronic Kidney Disease in Patients with Severe Obesity." Metabolites vol. 11,12 (2021). doi: https://doi.org/10.3390/metabo11120836
Lanzon B, Martin-Taboada M, Castro-Alves V, Vila-Bedmar R, González de Pablos I, Duberg D, Gomez P, Rodriguez E, Orešič M, Hyötyläinen T, Morales E, Ruperez FJ, Medina-Gomez G. Lipidomic and Metabolomic Signature of Progression of Chronic Kidney Disease in Patients with Severe Obesity. Metabolites. 2021 Dec 03;11(12). doi: 10.3390/metabo11120836. PMID: 34940593.
Copy Download .nbib Format: NLM
Stability of polycyclic aromatic hydrocarbons in pressurised hot water.

The Analyst

Andersson T, Hartonen K, Hyötyläinen T, Riekkola ML.
PMID: 12625555
Analyst. 2003 Feb;128(2):150-5. doi: 10.1039/b211447j.

The stability of seven polycyclic aromatic hydrocarbons (PAHs) were studied in aqueous solutions at 100-350 degrees C. The aqueous solution of one PAH compound at a time was sealed in a stainless steel bomb-type reaction vessel in an argon...

Cite
Andersson T, Hartonen K, Hyötyläinen T, et al. Stability of polycyclic aromatic hydrocarbons in pressurised hot water. Analyst. 2003;128(2):150-5doi: 10.1039/b211447j.
Andersson, T., Hartonen, K., Hyötyläinen, T., & Riekkola, M. L. (2003). Stability of polycyclic aromatic hydrocarbons in pressurised hot water. The Analyst, 128(2), 150-5. https://doi.org/10.1039/b211447j
Andersson, Terhi, et al. "Stability of polycyclic aromatic hydrocarbons in pressurised hot water." The Analyst vol. 128,2 (2003): 150-5. doi: https://doi.org/10.1039/b211447j
Andersson T, Hartonen K, Hyötyläinen T, Riekkola ML. Stability of polycyclic aromatic hydrocarbons in pressurised hot water. Analyst. 2003 Feb;128(2):150-5. doi: 10.1039/b211447j. PMID: 12625555.
Copy Download .nbib Format: NLM
Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride.

Cardiovascular diabetology

Jendle J, Hyötyläinen T, Orešič M, Nyström T.
PMID: 34920733
Cardiovasc Diabetol. 2021 Dec 17;20(1):237. doi: 10.1186/s12933-021-01431-2.

BACKGROUND: Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) leads to multiple metabolic changes, reduction in glucose levels and body weight are well established. In people with type 2 diabetes, GLP-1 RAs reduce the risk of cardiovascular (CV) disease...

Cite
Jendle J, Hyötyläinen T, Orešič M, et al. Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride. Cardiovasc Diabetol. 2021;20(1):237doi: 10.1186/s12933-021-01431-2.
Jendle, J., Hyötyläinen, T., Orešič, M., & Nyström, T. (2021). Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride. Cardiovascular diabetology, 20(1), 237. https://doi.org/10.1186/s12933-021-01431-2
Jendle, J, et al. "Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride." Cardiovascular diabetology vol. 20,1 (2021): 237. doi: https://doi.org/10.1186/s12933-021-01431-2
Jendle J, Hyötyläinen T, Orešič M, Nyström T. Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride. Cardiovasc Diabetol. 2021 Dec 17;20(1):237. doi: 10.1186/s12933-021-01431-2. PMID: 34920733.
Copy Download .nbib Format: NLM
Metabolic Signatures of the Exposome-Quantifying the Impact of Exposure to Environmental Chemicals on Human Health.

Metabolites

Orešič M, McGlinchey A, Wheelock CE, Hyötyläinen T.
PMID: 33182712
Metabolites. 2020 Nov 10;10(11). doi: 10.3390/metabo10110454.

Human health and well-being are intricately linked to environmental quality. Environmental exposures can have lifelong consequences. In particular, exposures during the vulnerable fetal or early development period can affect structure, physiology and metabolism, causing potential adverse, often permanent, health...

Cite
Orešič M, McGlinchey A, Wheelock CE, et al. Metabolic Signatures of the Exposome-Quantifying the Impact of Exposure to Environmental Chemicals on Human Health. Metabolites. 2020;10(11)doi: 10.3390/metabo10110454.
Orešič, M., McGlinchey, A., Wheelock, C. E., & Hyötyläinen, T. (2020). Metabolic Signatures of the Exposome-Quantifying the Impact of Exposure to Environmental Chemicals on Human Health. Metabolites, 10(11), . https://doi.org/10.3390/metabo10110454
Orešič, Matej, et al. "Metabolic Signatures of the Exposome-Quantifying the Impact of Exposure to Environmental Chemicals on Human Health." Metabolites vol. 10,11 (2020). doi: https://doi.org/10.3390/metabo10110454
Orešič M, McGlinchey A, Wheelock CE, Hyötyläinen T. Metabolic Signatures of the Exposome-Quantifying the Impact of Exposure to Environmental Chemicals on Human Health. Metabolites. 2020 Nov 10;10(11). doi: 10.3390/metabo10110454. PMID: 33182712; PMCID: PMC7698239.
Copy Download .nbib Format: NLM
Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests.

Nature reviews. Gastroenterology & hepatology

Masoodi M, Gastaldelli A, Hyötyläinen T, Arretxe E, Alonso C, Gaggini M, Brosnan J, Anstee QM, Millet O, Ortiz P, Mato JM, Dufour JF, Orešič M.
PMID: 34508238
Nat Rev Gastroenterol Hepatol. 2021 Dec;18(12):835-856. doi: 10.1038/s41575-021-00502-9. Epub 2021 Sep 10.

Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide and is often associated with aspects of metabolic syndrome. Despite its prevalence and the importance of early diagnosis, there is a lack of robustly validated...

Cite
Masoodi M, Gastaldelli A, Hyötyläinen T, et al. Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. Nat Rev Gastroenterol Hepatol. 2021;18(12):835-856doi: 10.1038/s41575-021-00502-9.
Masoodi, M., Gastaldelli, A., Hyötyläinen, T., Arretxe, E., Alonso, C., Gaggini, M., Brosnan, J., Anstee, Q. M., Millet, O., Ortiz, P., Mato, J. M., Dufour, J. F., & Orešič, M. (2021). Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. Nature reviews. Gastroenterology & hepatology, 18(12), 835-856. https://doi.org/10.1038/s41575-021-00502-9
Masoodi, Mojgan, et al. "Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests." Nature reviews. Gastroenterology & hepatology vol. 18,12 (2021): 835-856. doi: https://doi.org/10.1038/s41575-021-00502-9
Masoodi M, Gastaldelli A, Hyötyläinen T, Arretxe E, Alonso C, Gaggini M, Brosnan J, Anstee QM, Millet O, Ortiz P, Mato JM, Dufour JF, Orešič M. Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. Nat Rev Gastroenterol Hepatol. 2021 Dec;18(12):835-856. doi: 10.1038/s41575-021-00502-9. Epub 2021 Sep 10. PMID: 34508238.
Copy Download .nbib Format: NLM
Contribution of astrocytes to familial risk and clinical manifestation of schizophrenia.

Glia

Koskuvi M, Lehtonen Š, Trontti K, Keuters M, Wu YC, Koivisto H, Ludwig A, Plotnikova L, Virtanen PLJ, Räsänen N, Kaipainen S, Hyötyläinen I, Dhungana H, Giniatullina R, Ojansuu I, Vaurio O, Cannon TD, Lönnqvist J, Therman S, Suvisaari J, Kaprio J, Lähteenvuo M, Tohka J, Giniatullin R, Rivera C, Hovatta I, Tanila H, Tiihonen J, Koistinaho J.
PMID: 34936134
Glia. 2021 Dec 22; doi: 10.1002/glia.24131. Epub 2021 Dec 22.

Previous studies have implicated several brain cell types in schizophrenia (SCZ), but the genetic impact of astrocytes is unknown. Considering their high complexity in humans, astrocytes are likely key determinants of neurodevelopmental diseases, such as SCZ. Human induced pluripotent...

Cite
Koskuvi M, Lehtonen Š, Trontti K, et al. Contribution of astrocytes to familial risk and clinical manifestation of schizophrenia. Glia. 2021;doi: 10.1002/glia.24131.
Koskuvi, M., Lehtonen, �. �., Trontti, K., Keuters, M., Wu, Y. C., Koivisto, H., Ludwig, A., Plotnikova, L., Virtanen, P. L. J., Räsänen, N., Kaipainen, S., Hyötyläinen, I., Dhungana, H., Giniatullina, R., Ojansuu, I., Vaurio, O., Cannon, T. D., Lönnqvist, J., Therman, S., Suvisaari, J., Kaprio, J., Lähteenvuo, M., Tohka, J., Giniatullin, R., Rivera, C., Hovatta, I., Tanila, H., Tiihonen, J., & Koistinaho, J. (2021). Contribution of astrocytes to familial risk and clinical manifestation of schizophrenia. Glia, . https://doi.org/10.1002/glia.24131
Koskuvi, Marja, et al. "Contribution of astrocytes to familial risk and clinical manifestation of schizophrenia." Glia vol. (2021). doi: https://doi.org/10.1002/glia.24131
Koskuvi M, Lehtonen Š, Trontti K, Keuters M, Wu YC, Koivisto H, Ludwig A, Plotnikova L, Virtanen PLJ, Räsänen N, Kaipainen S, Hyötyläinen I, Dhungana H, Giniatullina R, Ojansuu I, Vaurio O, Cannon TD, Lönnqvist J, Therman S, Suvisaari J, Kaprio J, Lähteenvuo M, Tohka J, Giniatullin R, Rivera C, Hovatta I, Tanila H, Tiihonen J, Koistinaho J. Contribution of astrocytes to familial risk and clinical manifestation of schizophrenia. Glia. 2021 Dec 22; doi: 10.1002/glia.24131. Epub 2021 Dec 22. PMID: 34936134.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 48 entries